Disease-oriented approach to botulinum toxin use

Toxicon

Volumn 54, Issue 5, 2009, Pages 614-623

  Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Blepharospasm; Botulinum toxin; Bruxism; Camptocormia; Constipation; Dystonia; Parkinson disease; Sialorrhea

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; LEVODOPA; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

APRAXIA; AXIAL DYSTONIA; BLEPHAROSPASM; BLURRED VISION; BRUXISM; BULBAR PARALYSIS; CAMPTOCORMIA; CERVICAL DYSTONIA; CLINICAL TRIAL; CONSTIPATION; DIPLOPIA; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRY EYE; DYSPHAGIA; DYSTONIA; EPIPHORA; ESOPHAGUS ACHALASIA; ESSENTIAL TREMOR; EYELID DISEASE; FINGER INJURY; FOCAL DYSTONIA; FOOT DISEASE; FROZEN SHOULDER; GAIT DISORDER; HAND TREMOR; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; JAW DISEASE; LEG DISEASE; LIMB DISEASE; OVERACTIVE BLADDER; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PTOSIS; QUALITY OF LIFE; REPEATED DRUG DOSE; REVIEW; SCOLIOSIS; SEBORRHEA; TREATMENT RESPONSE; TREMOR; URINARY URGENCY; WEAKNESS; XEROSTOMIA;

APRAXIAS; BLEPHAROSPASM; BOTULINUM TOXINS; BRUXISM; DYSTONIC DISORDERS; GAIT DISORDERS, NEUROLOGIC; HUMANS; PARKINSON DISEASE; SIALORRHEA; TREMOR;

EID: 68949195990     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2008.11.013     Document Type: Review

References (110)

1. Albanese A., Brisinda G., Bentivoglio A.R., and Maria G. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am. J. Gastroenterol. 98 (2003) 1439-1440
2. Apostolidis A., and Fowler C.J. The use of botulinum neurotoxin type A (BoNTA) in urology. J. Neural. Transm. 115 (2008) 593-605
3. Araki I., and Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J. Neurol. Neurosurg. Psychiatry 68 (2000) 429-433
4. Aramideh M., Ongerboer de Visser B.W., Brans J.W., Koelman J.H., and Speelman J.D. Pretarsal application of botulinum toxin for treatment of blepharospasm. J. Neurol. Neurosurg. Psychiatry 59 (1995) 309-311
5. Ashour R., and Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov. Disord. 21 (2006) 1856-1863
6. Ashour R., Tintner R., and Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol. 4 (2005) 423-431
7. Azher S.N., and Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 65 (2005) 355-359
8. Azher S.N., and Jankovic J. Clinical aspects of progressive supranuclear palsy. In: Duyckaerts C., and Litvan I. (Eds). 3rd Series. Handbook of Clinical Neurology 89 (2008), Elsevier, Amsterdam, The Netherlands, Handb Clin Neurol 461-473
9. Bader G., and Lavigne G.J. Sleep bruxism: overview of an oromandibular sleep movement disorders. Sleep Med. Rev. 4 (2000) 27-43
10. Blitzer A., and Brin M.F. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol. Head Neck Surg. 116 (1997) 328-330
11. Bloch F., Houeto J.L., Tezenas du Montcel S., et al. Parkinson's disease with camptocormia. J. Neurol. Neurosurg. Psychiatry 77 (2006) 1223-1228
12. Bonanni L., Thomas A., Varanese S., Scorrano V., and Onofrj M. Botulinum toxin treatment of lateral axial dystonia in parkinsonism. Mov. Disord. 22 (2007) 2097-2103
13. Brin M.F., Lyons K.E., Doucette J., Adler C.H., Caviness J.N., Comella C.L., Dubinsky R.M., Friedman J.H., Manyam B.V., Matsumoto J.Y., Pullman S.L., Rajput A.H., Sethi K.D., Tanner C., and Coller W.C. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 56 (2001) 1523-1528
14. Cadeddu F., Bentivoglio A.R., Brandara F., Marniga G., Brisinda G., and Maria G. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment. Pharmacol. Ther. 22 (2005) 997-1003
15. Cakmur R., Ozturk V., Uzunel F., Donmez B., and Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J. Neurol. 249 (2002) 64-68
16. Chuang Y.C., and Chancellor M.B. The application of botulinum toxin in the prostate. J. Urol. 176 (2006) 2375-2382
17. Colosimo C., Chianese M., Giovannelli M., Contarino M.F., and Bentivoglio A.R. Botulinum toxin type B in blepharospasm and hemifacial spasm. J. Neurol. Neurosurg. Psychiatry 74 (2003) 687
18. Cordivari C., Misra P., Catania S., and Lees A.J. Treatment of dystonic clenched fist with botulinum toxin. Mov. Disord. 16 (2001) 907-913
19. Denny Brown D. The nature of apraxia. J. Nerv. Ment. Dis. 126 (1958) 9-31
20. Diamond A., and Jankovic J. Botulinum toxin in dermatology - beyond wrinkles and sweat. J. Cosmet. Dermatol. 5 (2006) 169
21. Diamond A., and Jankovic J. Treatment of advanced Parkinson's disease. Expert Rev. Neurother. 6 (2006) 1181-1197
22. Dogu O., Apaydin D., Sevim S., Talas D.U., and Aral M. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin. Neurol. Neurosurg. 106 (2004) 93-96
23. Dutton J.J., and Fowler A.M. Botulinum toxin in ophthalmology. Surv. Ophthalmol. 52 (2007) 13-31
24. Eaker E.Y., Gordon J.M., and Vogel S.B. Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia. Dig. Dis. Sci. 42 (1997) 724-727
25. Elston J.S. A new variant of blepharospasm. J. Neurol. Neurosurg. Psychiatry 55 (1992) 369-371
26. Erer S., and Jankovic J. Hereditary chin tremor in Parkinson's disease. Clin. Neurol. Neurosurg. 109 (2007) 784-785
27. Fernandez H.H., Lannon M.C., Trieschmann M.E., and Friedman J.H. Botulinum toxin type B for gait freezing in Parkinson's disease. Med. Sci. Monit. 10 (2004) 282-284
28. Forget R., Tozlovanu V., Iancu A., and Boghen D. Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology 25 58 (2002) 1843-1846
29. Friedman A., and Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat. Disord. 7 (2001) 329-332
30. Giladi N., and Honigman S. Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson's disease. Mov. Disord. 12 (1997) 1085-1086
31. Giladi N., Meer J., and Honigman S. The use of botulinum toxin to treat "striatal" toes. J. Neurol. Neurosurg. Psychiatry 57 (1994) 659
32. Giladi N., Gurevich S.H., Paleacu D., and Simon E.S. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J. Neurol. 248 (2001) 572-576
33. Giladi N., McDermott M.P., Fahn S., Przedborski S., Jankovic J., Stern M., Tanner C., and the Parkinson Study Group. Freezing of gait in PD. Prospective assessment of the DATATOP cohort. Neurology 56 (2001) 1712-1721
34. Girlanda P., Quartarone A., Sinicropi S., Nicolosi C., and Messina C. Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Mov. Disord. 11 (1996) 27-31
35. Gupta A.K., Bluhm R., Cooper E.A., Summerbell R.C., and Batra R. Seborrheic dermatitis. Dermatol. Clin. 21 (2003) 401-412
36. Gurevich T., Peretz C., Moore O., Weizmann N., and Giladi N. The effect of injecting botulinum toxin type A into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study. Mov. Disord. 22 (2007) 880-883
37. Hallett, M., Evinger, C., Jankovic, J., Stacy, M., 2008. Update on blepharospasm. Report from BEBRF International Workshop 2006. Neurology 71, 1275-82.
38. Hellmann M.A., Djaldetti R., Israel Z., and Melamed E. Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Mov. Disord. 21 (2006) 2008-2010
39. Henderson J.M., Ghika J.A., Van-Melle G., Haller E., and Einstein R. Botulinum toxin A in nondystonic tremors. Eur. Neurol. 36 (1996) 29-35
40. Herting B., Wunderlich S., Glockler T., et al. Computed tomographically-controlled injection of botulinum toxin into the longus colli muscle in severe anterocollis. Mov. Disord. 19 (2004) 588-590
41. Hirota N., Hirota M., and Mezaki T. Dystonic frowning without blepharospasm. Parkinsonism Relat. Disord. (1 Mar 2008) [Epub ahead of print]
42. Hunker C.J., and Abbs J.H. Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue and index finger. Mov. Disord. 5 (1990) 71-77
43. Inoue K., and Rogers J.D. Botulinum toxin injection into Riolan's muscle: somatosensory 'trick'. Eur. Neurol. 58 (2007) 138-141
44. Jankovic J., and Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37 (1987) 616-623
45. Jankovic J., and Schwartz K. Botulinum toxin treatment of tremors. Neurology 41 (1991) 1185-1188
46. Jankovic J., and Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21 (2007) 677-692
47. Jankovic J., and Tintner R. Dystonia and parkinsonism. Parkinsonism Relat. Disord. 8 (2001) 109-121
48. Jankovic J., Schwartz K., Clemence W., Aswad A., and Mordaunt J. A randomized double-blind, placebo controlled study to evaluate botulinum toxin A in essential hand tremor. Mov. Disord. 11 (1996) 250-256
49. Jankovic J., Schwartz K.S., and Ondo W. Re-emergent tremor of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67 (1999) 646-650
50. Jankovic J., Hunter C., Dolimbek B.Z., Dolimbek G.S., Adler C.H., Brashear A., Comella C.L., Gordon M., Riley D.E., Sethi K., Singer C., Stacy M., Tarsy D., and Atassi M.Z. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67 (2006) 2233-2235
51. Jankovic J., Albanese A., Atassi M.Z., Dolly J.O., Hallett M., and Mayer N. Botulinum and Other Neurotoxins: Translating Science into Therapeutic Applications (2008), Butterworth-Heinemann/Elsevier, Philadelphia, PA
52. Jankovic J. Apraxia of lid opening. Mov. Disord. 10 (1995) 686
53. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 75 (2004) 951-957
54. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20 Suppl. 11 (2005) S11-S16
55. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox. Res. 9 (2006) 145-148
56. Jankovic J. Treatment of dystonia. Lancet Neurol. 5 (2006) 864-872
57. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79 (2008) 368-376
58. Johnston B.T., Colcher A., Li Q., Gideon R.M., Castell J.A., and Castell D.O. Repetitive proximal esophageal contractions: a new manometric finding and a possible further link between Parkinson's disease and achalasia. Dysphagia 16 (2001) 186-189
59. Jost W.H. Treatment of drooling in Parkinson's disease with botulinum toxin. Mov. Disord. 14 (1999) 1057
60. Kenney C., and Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J. Neural. Transm. 115 (2008) 585-591
61. Krack P., and Marion M.H. 'Apraxia of lid opening.' A focal eyelid dystonia: clinical study of 32 patients. Mov. Disord. 9 (1994) 610-615
62. Kuo S.H., Kenney C., and Jankovic J. Bilateral pedunculopontine nuclei stroke presenting as freezing of gait. Mov. Disord. 23 (2008) 616-619
63. Lagalla G., Millevolte M., Capecci M., Provinciali L., and Ceravolo M.G. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov. Disord. 21 (2006) 704-707
64. Lepore V., Defazio G., Acquistapace D., et al. Botulinum A toxin for the so-called apraxia of lid opening. Mov. Disord. 10 (1995) 525-526
65. Lepoutre A.C., Devos D., Blanchard-Dauphin A., Pardessus V., Maurage C.A., Ferriby D., Hurtevent J.F., Cotten A., Destee A., and Defebvre L. A specific clinical pattern of camptocormia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 77 (2006) 1229-1234
66. Lim E.C., and Seet R.C. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurol. Scand. 117 (2008) 73-84
67. Lipp A., Trottenberg T., Schink T., Kupsch A., and Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61 (2003) 1279-1281
68. Mancini F., Zangaglia R., Cristina S., Sommaruga M.G., Martignoni E., Nappi G., and Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov. Disord. 18 (2003) 685-688
69. Mathers S.E., Kempster P.A., Swash M., and Lees A.J. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon?. J. Neurol. Neurosurg. Psychiatry 51 (1988) 1503-1507
70. Mejia N.I., Vuong K.D., and Jankovic J. Long-term botulinum toxin efficacy, safety and immunogenicity. Mov. Disord. 20 (2005) 592-597
71. Melamed E., and Djaldetti R. Camptocormia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 78 (2007) 1005-1006
72. Molho E., Jankovic J., and Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurol. Clin. 26 Suppl. 1 (2008) 43-53
73. Molloy L. Treatment of sialorrhoea in patients with Parkinson's disease: best current evidence. Curr. Opin. Neurol. 20 (2007) 493-498
74. Murray C.A., Cohen J.L., and Solish N. Treatment of focal hyperhidrosis. J. Cutan. Med. Surg. 11 (2007) 67-77
75. Naumann M., So Y., Argoff C.E., Childers M.K., Dykstra D.D., Gronseth G.S., Jabbari B., Kaufmann H.C., Schurch B., Silberstein S.D., and Simpson D.M. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70 (2008) 1707-1714
76. Nóbrega A.C., Rodrigues B., Torres A.C., Enzo A., and Melo A. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?. J. Neurol. Sci. 253 (2007) 85-87
77. Ondo W.G., Hunter C., and Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62 (2004) 37-40
78. Pacchetti C., Albani G., Martignoni E., Godi L., Alfonsi E., and Nappi G. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov. Disord. 10 (1995) 333-336
79. Pal P.K., Calne D.B., Calne S., and Tsui J.K. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54 (2000) 244-247
80. Papapetropoulos S., Baez S., Zitser J., Sengun C., and Singer C. Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. Eur. Neurol. 59 (2007) 71-75
81. Pasricha P.J., Ravich W.J., Hendrix T., et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N. Engl. J. Med. 322 (1995) 774-778
82. Patel A.K., Patterson J.M., and Chapple C.R. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur. Urol. 50 (2006) 684-709
83. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2 (2003) 107-116
84. Pinnington L.L., Muhiddin K.A., Ellis R.E., and Playford E.D. Non-invasive assessment of swallowing and respiration in Parkinson's disease. J. Neurol. 247 (2000) 773-777
85. Pohl D., and Tutuian R. Achalasia: an overview of diagnosis and treatment. J. Gastrointestin. Liver Dis. 16 (2007) 297-303
86. Proulx de Courval F.P., Wiseman M.A., and Panisset M. Salivary production in Parkinson's disease. Mov. Disord. 20 (2005) 204-247
87. Pursiainen V., Haapaniemi T.H., Korpelainen J.T., Sotaniemi K.A., and Myllyla V.V. Sweating in parkinsonian patients with wearing-off. Mov. Disord. 22 (2007) 828-832
88. Racette B.A., Good L., Sagitto S., and Perlmutter J.S. Botulinum toxin B reduces sialorrhea in parkinsonism. Mov. Disord. 18 (2003) 1059-1061
89. Rieder C.R., Schestatsky P., Socal M.P., Monte T.L., Fricke D., Costa J., and Picon P.D. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin. Neuropharmacol. 30 (2007) 39-42
90. Roggenkamper P., Jost W.H., Bihari K., Comes G., Grafe S., and for the NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J. Neural. Transm. 113 (2006) 303-312
91. Sakakibara R., Odaka T., Uchiyama T., Asahina M., Yamaguchi K., Yamaguchi T., Yamanishi T., and Hattori T. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 74 (2003) 268-272
92. Santamato A., Ianieri G., Ranieri M., Megna M., Panza F., Fiore P., and Megna G. Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease. J. Am. Geriatr. Soc. 56 (2008) 765-767
93. Schestatsky P., Valls-Sole J., Ehlers J.A., Rieder C.R., and Gomes I. Hyperhidrosis in Parkinson's disease. Mov. Disord. 21 (2006) 1744-1748
94. Schiano T.D., Parkman H.P., Miller L.S., et al. Use of botulinum toxin in the treatment of achalasia. Dig. Dis. 16 (1998) 14-22
95. Schneider S.A., Edwards M.J., Cordivari C., Macleod W.N., and Bhatia K.P. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease. Mov. Disord. 21 (2006) 1722-1724
96. Sheffield J.K., and Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev. Neurother. 7 (2007) 637-647
97. Simpson D.M., Blitzer A., Brashear A., Comella C., Dubinsky R., Hallett M., Jankovic J., Karp B., Ludlow C.L., Miyasaki J.M., Naumann M., and So Y. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70 (2008) 1699-1706
98. Solish N., Bertucci V., Dansereau A., Hong H.C., Lynde C., Lupin M., Smith K.C., and Storwick G. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian hyperhidrosis advisory committee. Dermatol. Surg. 33 (2007) 908-923
99. Soonawala N., Bhatia K.P., Yeung J.H.M., et al. Idiopathic blepharospasm does not lead to a parkinsonian syndrome: results of a questionnaire-based follow-up study. J. Neurol. 246 (1999) 283-286
100. Swinn L., Schrag A., Viswanathan R., et al. Sweating dysfunction in Parkinson's disease. Mov. Disord. 18 (2003) 1459-1463
101. Tan E.K., and Jankovic J. Treating severe bruxism with botulinum toxin. J. Am. Dent. Assoc. 131 (2000) 211-216
102. Tintner R., Gross R., Winzer U.F., Smalky K.A., and Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 65 (2005) 765-767
103. Trosch R.M., and Pullman S.C. Botulinum toxin A injections for the treatment of hand tremor. Mov. Disord. 9 (1994) 601-609
104. Truong D.D., and Jost W.H. Botulinum toxin: clinical use. Parkinsonism Relat. Disord. 12 (2006) 331-355
105. ®) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat. Disord. 4, 407-14.
106. Tscheng D.Z. Sialorrhea - therapeutic drug options. Ann. Pharmacother. 36 (2002) 1785-1790
107. Tumilasci O.R., Cersosimo M.G., Belforte J.E., Micheli F.E., Benarroch E.E., and Pazo J.H. Quantitative study of salivary secretion in Parkinson's disease. Mov. Disord. 21 (2006) 660-667
108. van de Warrenburg B.P., Cordivari C., Ryan A.M., et al. The phenomenon of disproportionate antecollis in Parkinson's disease and multiple system atrophy. Mov. Disord. 22 (2007) 2325-2331
109. von Coelln R., Raible A., Gasser T., and Asmus F. Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov. Disord. 23 (2008) 889-892
110. Wieler M., Camicioli R., Jones C.A., and Martin W.R. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology 65 (2005) 626-628